Of relevance, because a specific small molecule inhibitor of HIF2α (belzutifan) has been recently approved by the U.S. FDA (Food and Drugs Administration) for the treatment of adult patients with VHL disease associated with renal cell carcinoma or pancreatic tumors, future studies into this pathway may pave the way for the use of this compound in other malignancies including blood cancers. This evidence concerns the gene EPAS1 and renal cell carcinoma.